[1] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020; 396, 1204−22. doi:  10.1016/S0140-6736(20)30925-9
[2] Hankey GJ. Stroke. Lancet, 2017; 389, 641−54. doi:  10.1016/S0140-6736(16)30962-X
[3] Wang YJ, Li ZX, Gu HQ, et al. China Stroke Statistics: an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. Stroke Vasc Neurol, 2022; 7, 415−50. doi:  10.1136/svn-2021-001374
[4] Cuenca-López MD, Brea D, Segura T, et al. [Inflammation as a therapeutic agent in cerebral infarction: cellular inflammatory response and inflammatory mediators]. Rev Neurol, 2010; 50, 349−59.
[5] Rudd PM, Wormald MR, Dwek RA. Glycosylation and the immune system. J Protein Chem, 1998; 17, 519.
[6] Kronimus Y, Dodel R, Galuska SP, et al. IgG Fc N-glycosylation: alterations in neurologic diseases and potential therapeutic target? J Autoimmun, 2019; 96, 14-23.
[7] Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci, 2012; 1253, 170−80. doi:  10.1111/j.1749-6632.2011.06305.x
[8] Russell A, Adua E, Ugrina I, et al. Unravelling immunoglobulin G Fc N-glycosylation: a dynamic marker potentiating predictive, preventive and personalised medicine. Int J Mol Sci, 2018; 19, 390. doi:  10.3390/ijms19020390
[9] Varki A. Biological roles of glycans. Glycobiology, 2017; 27, 3−49. doi:  10.1093/glycob/cww086
[10] Krištić J, Zaytseva OO, Ram R, et al. Profiling and genetic control of the murine immunoglobulin G glycome. Nat Chem Biol, 2018; 14, 516−24. doi:  10.1038/s41589-018-0034-3
[11] Zaytseva OO, Seeling M, Krištić J, et al. Fc-linked IgG N-glycosylation in FcγR knock-out mice. Front Cell Dev Biol, 2020; 8, 67. doi:  10.3389/fcell.2020.00067
[12] Klarić L, Tsepilov YA, Stanton CM, et al. Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases. Sci Adv, 2020; 6, eaax0301. doi:  10.1126/sciadv.aax0301
[13] Knezević A, Polašek O, Gornik O, et al. Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res, 2009; 8, 694−701. doi:  10.1021/pr800737u
[14] Novokmet M, Lukić E, Vučković F, et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep, 2014; 4, 4347. doi:  10.1038/srep04347
[15] Liu D, Zhao ZY, Wang AX, et al. Ischemic stroke is associated with the pro-inflammatory potential of N-glycosylated immunoglobulin G. J Neuroinflammation, 2018; 15, 123. doi:  10.1186/s12974-018-1161-1
[16] Liu D, Li Q, Dong J, et al. The association between normal BMI with central adiposity and proinflammatory potential immunoglobulin G N-glycosylation. Diabetes Metab Syndr Obes, 2019; 12, 2373−85. doi:  10.2147/DMSO.S216318
[17] Greto VL, Cvetko A, Štambuk T, et al. Extensive weight loss reduces glycan age by altering IgG N-glycosylation. Int J Obes (Lond), 2021; 45, 1521−31. doi:  10.1038/s41366-021-00816-3
[18] Gao Q, Dolikun M, Štambuk J, et al. Immunoglobulin G N-glycans as potential postgenomic biomarkers for hypertension in the Kazakh population. OMICS, 2017; 21, 380−9. doi:  10.1089/omi.2017.0044
[19] Wang YX, Klarić L, Yu XW, et al. The association between glycosylation of immunoglobulin g and hypertension: a multiple ethnic cross-sectional study. Medicine (Baltimore), 2016; 95, e3379. doi:  10.1097/MD.0000000000003379
[20] Lemmers RFH, Vilaj M, Urda D, et al. IgG glycan patterns are associated with type 2 diabetes in independent European populations. Biochim Biophys Acta Gen Subj, 2017; 1861, 2240−9. doi:  10.1016/j.bbagen.2017.06.020
[21] Liu D, Chu X, Wang H, et al. The changes of immunoglobulin G N-glycosylation in blood lipids and dyslipidaemia. J Transl Med, 2018; 16, 235. doi:  10.1186/s12967-018-1616-2
[22] Cvetko A, Kifer D, Gornik O, et al. Glycosylation alterations in multiple sclerosis show increased proinflammatory potential. Biomedicines, 2020; 8, 410. doi:  10.3390/biomedicines8100410
[23] Ząbczyńska M, Link-Lenczowski P, Novokmet M, et al. Altered N-glycan profile of IgG-depleted serum proteins in Hashimoto's thyroiditis. Biochim Biophys Acta Gen Subj, 2020; 1864, 129464. doi:  10.1016/j.bbagen.2019.129464
[24] Sun Y, Wang YX, Zhang J, et al. Comparison of gender specific structure profiles of immunoglobulin G N-glycans. Chin J Epidemiol, 2016; 37, 1409−12. (In Chinese
[25] Krištić J, Vučković F, Menni C, et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol A Biol Sci Med Sci, 2014; 69, 779−89. doi:  10.1093/gerona/glt190
[26] Ercan A, Kohrt WM, Cui J, et al. Estrogens regulate glycosylation of IgG in women and men. JCI Insight, 2017; 2, e89703.
[27] Wang YX, Ge SQ, Yan YX, et al. China suboptimal health cohort study: rationale, design and baseline characteristics. J Transl Med, 2016; 14, 291. doi:  10.1186/s12967-016-1046-y
[28] World Health Organization. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke, 1989; 20, 1407−31. doi:  10.1161/01.STR.20.10.1407
[29] Haslam DW, James WPT. Obesity. Lancet, 2005; 366, 1197−1209. doi:  10.1016/S0140-6736(05)67483-1
[30] Yu CZ, Wang J, Li YR, et al. Exposure to the Chinese famine in early life and hypertension prevalence risk in adults. J Hypertens, 2017; 35, 63−8. doi:  10.1097/HJH.0000000000001122
[31] Wang S, Xu L, Jonas JB, et al. Prevalence and associated factors of dyslipidemia in the adult Chinese population. PLoS One, 2011; 6, e17326. doi:  10.1371/journal.pone.0017326
[32] John M Cruickshank. Follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2009; 360, 417−8.
[33] Liu D, Xu XZ, Li YJ, et al. Immunoglobulin G N-glycan analysis by ultra-performance liquid chromatography. J Vis Exp,doi:  10.3791/60104.
[34] Meng XN, Song MS, Vilaj M, et al. Glycosylation of IgG Associates with hypertension and type 2 diabetes mellitus comorbidity in the Chinese Muslim ethnic minorities and the Han Chinese. J Pers Med, 2021; 11, 614. doi:  10.3390/jpm11070614
[35] Trbojević-Akmačić I, Vilaj M, Lauc G. High-throughput analysis of immunoglobulin G glycosylation. Expert Rev Proteomics, 2016; 13, 523−34. doi:  10.1080/14789450.2016.1174584
[36] Pučić-Baković M. High-throughput analysis of the IgG N-Glycome by UPLC-FLR. In: Lauc G, Wuhrer M. High-Throughput Glycomics and Glycoproteomics. Humana Press. 2017, 21-29.
[37] Pučić M, Knežević A, Vidič J, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics, 2011; 10, M111.010090. doi:  10.1074/mcp.M111.010090
[38] Wu GY, Wan X, Xu BH. A new estimation of protein-level false discovery rate. BMC Genomics, 2018; 19, 567. doi:  10.1186/s12864-018-4923-3
[39] Peng CY, Manz BD, Keck J. Modeling categorical variables by logistic regression. Am J Health Behav, 2001; 25, 278−84. doi:  10.5993/AJHB.25.3.15
[40] Witten DM, Tibshirani R. Covariance-regularized regression and classification for high dimensional problems. J Roy Stat Soc Series B Stat Methodol, 2009; 71, 615−36. doi:  10.1111/j.1467-9868.2009.00699.x
[41] Ding N, Nie H, Sun XM, et al. Human serum N-glycan profiles are age and sex dependent. Age Ageing, 2011; 40, 568−75. doi:  10.1093/ageing/afr084
[42] Wittenbecher C, Štambuk T, Kuxhaus O, et al. Plasma N-Glycans as emerging biomarkers of cardiometabolic risk: a prospective investigation in the EPIC-potsdam cohort study. Diabetes Care, 2020; 43, 661−8. doi:  10.2337/dc19-1507
[43] Štambuk T, Klasić M, Zoldoš V, et al. N-glycans as functional effectors of genetic and epigenetic disease risk. Mol Aspects Med, 2021; 79, 100891. doi:  10.1016/j.mam.2020.100891
[44] Vilar-Bergua A, Riba-Llena I, Vanhooren V, et al. N-glycome profile levels relate to silent brain infarcts in a cohort of hypertensives. J Am Heart Assoc, 2015; 4, e002669. doi:  10.1161/JAHA.115.002669
[45] Menni C, Gudelj I, Macdonald-Dunlop E, et al. Glycosylation profile of immunoglobulin G is cross-sectionally associated with cardiovascular disease risk score and subclinical atherosclerosis in two independent cohorts. Circ Res, 2018; 122, 1555−64. doi:  10.1161/CIRCRESAHA.117.312174
[46] Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 2006; 313, 670−3. doi:  10.1126/science.1129594
[47] Nikolac Perkovic M, Pucic Bakovic M, Kristic J, et al. The association between galactosylation of immunoglobulin G and body mass index. Prog Neuropsychopharmacol Biol Psychiatry, 2014; 48, 20−5. doi:  10.1016/j.pnpbp.2013.08.014
[48] Russell AC, Kepka A, Trbojević-Akmačić I, et al. Increased central adiposity is associated with pro-inflammatory immunoglobulin G N-glycans. Immunobiology, 2019; 224, 110−5. doi:  10.1016/j.imbio.2018.10.002
[49] Matsumoto A, Shikata K, Takeuchi F, et al. Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J Biochem, 2000; 128, 621−8. doi:  10.1093/oxfordjournals.jbchem.a022794
[50] Ackerman ME, Crispin M, Yu XJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest, 2013; 123, 2183−92. doi:  10.1172/JCI65708
[51] Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol, 2014; 5, 520.